title: Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
abstract: Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674 consecutive adult patients who were prospectively enrolled in the French PAH registry (121 incident and 553 prevalent cases). Two survival analyses were performed. First, the cohort of 674 patients was followed for 3 yrs after study entry and survival rates described. Then, we focused on the subset with incident idiopathic, familial and anorexigen-associated PAH (n = 56) combined with prevalent patients who were diagnosed <3 yrs prior to study entry (n = 134). In the cohort of 674 patients, 1-, 2-, and 3-yr survival rates were 87% (95% CI 84-90), 76% (95% CI 73-80), and 67% (95% CI 63-71), respectively. In prevalent idiopathic, familial and anorexigen-associated PAH, 1-, 2-, and 3-yr survival rates were higher than in incident patients (p = 0.037). In the combined cohort of patients with idiopathic, familial and anorexigen-associated PAH, multivariable analysis showed that survival could be estimated by means of a novel risk-prediction equation using patient sex, 6-min walk distance, and cardiac output at diagnosis. This study highlights survivor bias in prevalent cohorts of PAH patients. Survival of idiopathic, familial and anorexigen-associated PAH can be characterised by means of a novel risk-prediction equation using patients' characteristics at diagnosis.
authors.affiliation: Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Assistance-Publique-Hôpitaux de Paris, Université Paris-Sud 11, 157 rue de la Porte de Trivaux, 92140 Clamart, France. marc.humbert@abc.aphp.fr
authors.forename: M
authors.initials: M
authors.lastname: Humbert
authors.forename: O
authors.initials: O
authors.lastname: Sitbon
authors.forename: A
authors.initials: A
authors.lastname: Yaïci
authors.forename: D
authors.initials: D
authors.lastname: Montani
authors.forename: D S
authors.initials: DS
authors.lastname: O'Callaghan
authors.forename: X
authors.initials: X
authors.lastname: Jaïs
authors.forename: F
authors.initials: F
authors.lastname: Parent
authors.forename: L
authors.initials: L
authors.lastname: Savale
authors.forename: D
authors.initials: D
authors.lastname: Natali
authors.forename: S
authors.initials: S
authors.lastname: Günther
authors.forename: A
authors.initials: A
authors.lastname: Chaouat
authors.forename: F
authors.initials: F
authors.lastname: Chabot
authors.forename: J-F
authors.initials: JF
authors.lastname: Cordier
authors.forename: G
authors.initials: G
authors.lastname: Habib
authors.forename: V
authors.initials: V
authors.lastname: Gressin
authors.forename: Z-C
authors.initials: ZC
authors.lastname: Jing
authors.forename: R
authors.initials: R
authors.lastname: Souza
authors.forename: G
authors.initials: G
authors.lastname: Simonneau
mesh_terms: D000368:Aged; D015331:Cohort Studies; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000453:epidemiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D015272:Pulmonary Medicine / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome